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Abstract
Objectives: Intracranial hemorrhage (ICH) after acute stroke thrombolysis is associated with poor
outcomes. Previous investigations of the relationship between preexisting antiplatelet use and the safety
of intravenous (IV) thrombolysis have been limited by low event rates. The objective of this study was to
determine whether preexisting antiplatelet therapy increased the risk of ICH following acute stroke
thrombolysis. The primary hypothesis was that antiplatelet use would not be associated with
radiographic evidence of ICH after controlling for relevant confounders.
Methods: Consecutive cases of thrombolysis patients treated in the emergency department (ED) were
identified using multiple methods. Retrospective data were collected from four hospitals from 1996 to
2004 and 24 other hospitals from 2007 to 2010 as part of a cluster-randomized trial. The same chart
abstraction tool was used during both time periods, and data were subjected to numerous quality control
checks. Hemorrhages were classified using a prespecified methodology: ICH was defined as presence of
hemorrhage in radiographic interpretations of follow-up imaging (primary outcome). Symptomatic ICH
(sICH) was defined as radiographic ICH with associated clinical worsening. A multivariable logistic
regression model was constructed to adjust for clinical factors previously identified to be related to
postthrombolysis ICH. Sensitivity analyses were conducted where the unadjusted and adjusted results
from this study were combined with those of previously published external studies on this topic via
meta-analytic techniques.
Results: There were 830 patients included, with 47% having documented preexisting antiplatelet
treatment. The mean ( standard deviation [SD]) age was 69 (15) years, and the cohort was 53% male.
The unadjusted proportion of patients with any ICH was 15.1% without antiplatelet use and 19.3% with
antiplatelet use (absolute risk difference = 4.2%, 95% confidence interval [CI] = 1.2% to 9.6%); for sICH
this was 6.1% without antiplatelet use and 9% with antiplatelet use (absolute risk difference = 3.1%, 95%
CI = 1% to 6.7%). After adjusting for confounders, antiplatelet use was not significantly associated with
radiographic ICH (odds ratio [OR] = 1.1, 95% CI = 0.8 to 1.7) or sICH (OR = 1.3, 95% CI = 0.7 to 2.2). In
patients 81 years and older, there was a higher risk of radiographic ICH (absolute risk
difference = 11.9%, 95% CI = 0.1% to 23.6%). The meta-analyses combined the findings of this
investigation with previous similar work and found increased unadjusted risks of radiographic ICH
(absolute risk difference = 4.9%, 95% CI = 0.7% to 9%) and sICH (absolute risk difference = 4%, 95%
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CI = 2.3% to 5.6%). The meta-analytic adjusted OR of sICH for antiplatelet use was 1.6 (95% CI = 1.1 to
2.4).
Conclusions: The authors did not find that preexisting antiplatelet use was associated with
postthrombolysis ICH or sICH in this cohort of community treated patients. Preexisting tobacco use,
younger age, and lower severity were associated with lower odds of sICH. The meta-analyses
demonstrated small, but statistically significant increases in the absolute risk of radiographic ICH and
sICH, along with increased odds of sICH in patients with preexisting antiplatelet use.
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Treatment of acute stroke with tissue plasminogenactivator (tPA) reduces disability in appropriatelyselected patients.1, 2 Concerns over safety, specif-
ically symptomatic intracranial hemorrhage (sICH), have
contributed to relatively limited use of this treatment
and slow universal acceptance in emergency medicine.3
To address these concerns and improve patient out-
comes, the development of prediction rules to select
patients who have a lower risk of post-tPA sICH is a
high priority. To date, such decision rules have had lim-
ited discriminatory ability.4, 5
In the setting of ST-segment elevation myocardial
infarction, the combination of thrombolytics with a vari-
ety of antiplatelet agents and anticoagulants is safe and
efficacious.6 The same has not been established in
stroke. An early randomized controlled thrombolysis
trial in acute stroke found that the combination of aspi-
rin and streptokinase increased the risk of sICH com-
pared to streptokinase alone.7 Subsequent stroke tPA
trials treatment protocols mandated subjects not receive
antiplatelet treatment until 24 hours posttreatment.1, 2, 8
Following demonstration of tPA efficacy in the NINDS
tPA stroke study, this restriction on posttreatment anti-
platelet use became part of the U.S. Food and Drug
Administration–approved package insert. The same tri-
als did not, however, exclude patients with preexisting
antiplatelet use from study entry, despite the relatively
long duration of effect of most antiplatelet agents (aspi-
rin, clopidogrel).
Because patients with prior antiplatelet use have
been included in stroke thrombolysis trials and post-
marketing surveillance observational studies, several
retrospective investigations have provided conflicting
conclusions regarding the relationship between anti-
platelet use and ICH.9–16 Unadjusted analyses typically
show a higher absolute risk of ICH in patients with
existing antiplatelet use, but adjusted analyses account-
ing for age, severity, and other potential confounders
have been conflicting. Therefore, our objective was to
determine whether preexisting antiplatelet therapy was
associated with ICH following tPA treatment for ische-
mic stroke, with particular exploration of the effects of
age, as many studies have restricted thrombolysis
patients to those younger than 80 years. The primary
hypothesis was that antiplatelet use would not be asso-
ciated with radiographic evidence of ICH after control-
ling for relevant confounders. Our secondary




This was a secondary, retrospective, observational study
using data collected in two studies of tPA use in stroke
in Michigan: the Safety of Intravenous Thrombolysis in
Four Emergency Departments (SIT-ED) project and the
Increasing Stroke Treatment through Interventional
Behavior Change Tactics (INSTINCT) trial, which have
been previously described.17, 18 The University of Michi-
gan institutional review board (IRB) and all applicable
local IRBs approved the protocols for SIT-ED and
INSTINCT.
Study Setting and Population
The SIT-ED project was a retrospective case series of all
stroke patients receiving tPA within four hospitals;
INSTINCT was a cluster-randomized trial including all
cases of stroke tPA treatment within 24 randomly
selected community hospitals. All stroke patients aged
18 years or greater receiving IV tPA were identified
from all 28 hospitals during the study periods. Cases
were identified by several methods, including ED logs,
institutional stroke registries, pharmacy medication
administration records, and hospital billing records.
Clinical data were only available from the index hospi-
talizations; however, full records of the initial hospital-
izations were obtained for cases that were transferred
from an INSTINCT hospital to an institution not partici-
pating in the trial.
Study Protocol
Data were collected from four hospitals associated
with the SIT-ED project (1996 to 2004) and 24 addi-
tional community hospitals located in the Lower Penin-
sula of Michigan from the INSTINCT trial (2007–2010).
The general characteristics of the hospitals from both
studies are summarized in Table 1. The same data col-
lection instrument and quality control processes were
used for both studies. Trained clinical abstractors col-
lected all the data from source documents, double
review of key data elements was conducted, and
agreement was excellent, with agreement of 99% for
key data elements (thrombolysis inclusion criteria,
presence of ICH). The abstractors were not aware of
this study hypothesis when collecting data, as this
investigation was designed after the completion of data
analysis for both the SIT-ED project and the INSTINCT
trial.
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Patient-level data including age, sex, stroke risk fac-
tors, and self-reported ethnicity were obtained from the
medical record. Time of onset or time last known well
was recorded when it was explicitly stated in the medi-
cal record. When not specifically documented, the
National Institutes of Health Stroke Scale (NIHSS) score
was estimated using a previously described method.19
Preexisting use of antiplatelet agents was a binary field
in the data collection instrument and was determined
by study team abstractors. The last recorded blood
pressure prior to treatment and first recorded blood
glucose were abstracted from the ED record as pre-
treatment variables. Posttreatment protocol deviations
were defined as antiplatelet or anticoagulant use within
24 hours of tPA treatment or blood pressure not treated
when out of range for two or more measurements at
least 30 minutes apart.
Hemorrhages were classified using a prespecified
methodology: ICH was defined as presence of hemor-
rhage in radiographic interpretations (primary outcome
of this investigation) of any follow-up neuroimaging
(computed tomography [CT] or magnetic resonance
imaging [MRI]) obtained during initial hospitalization.
The timing of follow-up neuroimaging was at the dis-
cretion of the treating teams; the reports of all neuroi-
maging studies obtained during the first 10 days of the
initial hospitalization were reviewed. The main second-
ary outcome was sICH, defined as radiographic ICH
with associated clinical worsening based on retrospec-
tive review of hospital chart (NINDS tPA trial defini-
tion).
Sample Size
Prior to conducting the analysis, we hypothesized that a
clinically meaningful increase in the radiographic ICH
rate would be from 17% to 25.3% (50% relative
increase). Using a two-sided binomial difference in pro-
portions, with a significance level (alpha) of 0.05 and
80% power, a sample size of 377 patients per group
(with and without antiplatelets) was estimated. To detect
a 25% relative increase (range = 17% to 21.25%), 1,341
patients per group would be needed; to detect a 100%
relative increase (range = 17% to 34%), 101 patients per
group would be needed.
Data Analysis
Demographics and clinical characteristics are summa-
rized using descriptive statistics (means with standard
deviation [SD], medians with interquartile ranges
[IQR], or proportions as appropriate). The raw propor-
tions for the primary outcome for patients with and
without preexisting antiplatelet use and the 95% confi-
dence interval (CI) for the difference were calculated.
A multivariable logistic regression model was fitted to
adjust for clinical factors previously identified to be
related to postthrombolysis ICH with all variables
selected a priori. In addition to our variable of interest,
preexisting antiplatelet use, the model included age,
NIHSS, pretreatment systolic blood pressure, onset to
treatment interval, pretreatment blood glucose, tobacco
use, and presence of posttreatment protocol violations.
Continuous variables other than onset to treatment
interval were divided into quartiles to allow for potential
Table 1
Characteristics of the Study Hospitals
SIT-ED Hospital Characteristics
Hospital Location Urban/Rural Inpatient Beds Adult ED Volume Teaching Hospital Neurology
1 Ann Arbor Urban 792 50,918 Yes Yes
2 Ypsilanti Urban 529 65,259 Yes Yes
3 Flint Urban 463 54,707* Yes Yes
4 Jackson Rural 411 52,500 No Yes












Teaching hospital 11 (46)
Neurology available 22 (92)
Primary stroke center 8 (33)
Urban 8 (33)
Characteristics of the hospitals included from 1996–2004 (SIT-ED) and 2007–2010 (INSTINCT). Different data collection strategies
were used to summarize hospital data.
INSTINCT = Increasing Stroke Treatment through Interventional Behavior Change Tactics; SIT-ED = Safety of Intravenous
Thrombolysis in Four Emergency Departments.
*This hospital reported combined adult and pediatric volume.
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nonlinear associations between the selected covariates
and the outcome. Due to fewer sICH events, the multi-
variable model for this endpoint was constructed with
continuous variables dichotomized. In addition, a pro-
pensity score was calculated using logistic regression
for each case to provide a single summary measure of
the likelihood that any individual was on an antiplatelet
agent given his or her age, sex, race, and vascular risk
factor profile.20 This was then added as a covariate to
the final models measuring the association between
ICH and antiplatelet use. The Cochran-Armitage test
was used to assess for a trend in the rate of ICH over
time; this was performed because neuroimaging use
has changed over the time period. Specifically, MRI
has become more common and may detect more
ICH.21 In addition, the risk difference for ICH compar-
ing those with antiplatelet use to those without was
calculated within each age quartile. SAS version 9.2
(SAS Corporation, Cary, NC) was used for analysis.
We fitted the final main outcome model using two
alternative techniques to account for clustering within
hospitals—specifically hierarchical logistic regression
with a random intercept for hospital and a logistic
regression using a generalized estimating equation
(GEE) accounting for clustering within hospitals. In
addition, we calculated the radiographic and symptom-
atic ICH rates based on whether the patient had a fol-
low-up CT versus MRI.
Sensitivity Analysis
To put the current investigation in the context of the
previous understanding of the topic, we performed a
structured literature review and used meta-analytic
techniques to quantify how this investigation has
updated our knowledge. To identify relevant studies, a
PubMed search was conducted using the following
search logic (thrombolys* OR alteplase OR tPA) AND
stroke AND platelet aggregation inhibitors AND (cere-
bral hemorrhage OR intracranial hemorrhages). Studies
were included if they reported the unadjusted propor-
tions of patients with radiographic and/or sICH in
accordance with the PRISMA statement.22 Studies that
reported a subset of our four summary measures (unad-
justed risk difference for radiographic ICH, unadjusted
risk difference for sICH, adjusted odds ratio [aOR] for
radiographic ICH, and aOR for sICH) were included in
only the relevant analyses. For studies that used multi-
ple definitions of sICH, the NINDS definition (any ICH
plus any increased NIHSS or death within 1 week) was
used, as this definition is conservative (generally assign-
ing the highest proportion of hemorrhages to the symp-
tomatic category) and has been most commonly
reported across studies.1 The DerSimonian and Laird
random-effects model was used to calculate a pooled
estimate for the probability of radiographic and symp-
tomatic hemorrhage following tPA for cases with and
without preexisting antiplatelet use. In addition, esti-
mates of the aOR for the association relating antiplatelet
use to radiographic and sICH from the current and
previous investigations were also combined using the
DerSimonian and Laird method. R version 2.12.2 and R
package meta (R Project, Institute for Statistics and
Mathematics, WU Wein, Vienna, Austria), which
includes functions for performing meta-analyses of
studies reporting proportions and ORs, were used to
conduct this portion of the analysis.23 In the main analy-
ses, patients without follow-up neuroimaging were
assumed to be free of ICH, as the clinical teams may
have elected to not perform repeat imaging in patients
who were doing well.
RESULTS
Participants
A total of 830 patients were included (SIT-ED, n = 273;
INSTINCT, n = 557). The clinical characteristics of the
patients are summarized in Table 2. A total of 388
patients (47%) had documented histories of taking anti-
platelet agents. Patients with documented antiplatelet
use had higher burdens of stroke and cardiovascular
risk factors. Stroke severity and patient age were also
higher in the antiplatelet group.
Outcome Data
Radiographic ICH was observed in 67 patients (15.2%)
without preexisting antiplatelet use and 75 patients
(19.3%) with preexisting antiplatelet use. The absolute
difference was 4.2% (95% CI = 1.2% to 9.6%). Symp-
tomatic ICH was observed in 27 patients (6.1%) without
and 35 patients (9%) with preexisting antiplatelet use;
the absolute difference was 3.1% (95% CI = 1% to
6.7%).
Main Results
In the fully adjusted model, there was no association of
preexisting antiplatelet use with the primary outcome,
radiographic ICH (aOR = 1.13, 95% CI = 0.76 to 1.68).
Increasing severity, older age, and higher baseline
blood glucose were associated with presence of any
radiographic ICH. No association between antiplatelet
use was seen with sICH (see Table 3). Patients who had
a history of tobacco use had lower odds of sICH in the
fully adjusted analysis. When the propensity score was
added to these models, no meaningful change in the
estimated associations was observed (data not shown).
In addition, the hierarchical model and the GEE did not
demonstrate a substantial effect of clustering within
hospital (data not shown).
Secondary Results
There was no increase in the presence of any radio-
graphic ICH or sICH over time (see Data Supplement
S1, available as supporting information in the online
version of this paper). In the results stratified by age,
there was an observed increased risk of radiographic
ICH in patients 81 and older (11.9% absolute increase)
who were taking antiplatelet agents compared to those
who were not (Table 4). In 312 patients with follow-up
MRI, 12 had sICH (3.9%) and 41 had radiographic ICH
(13.1%). In the group of 468 patients without follow-up
MRI, there were 413 with one or more follow-up CT
and 55 with no follow-up neuroimaging; in this group
there were 50 sICH (9.7%) and 101 radiographic ICH
(19.5%). Of the 55 without follow-up neuroimaging, only
eight had clinical worsening compared to arrival at the
time of hospital discharge.
ACADEMIC EMERGENCY MEDICINE • February 2013, Vol. 20, No. 2 • www.aemj.org 149
Sensitivity Analysis
The pooled estimate for the excess risk in antiplatelet-
treated thrombolysis patients across all seven identified
studies in the meta-analysis was 4.9% (95% CI = 0.7%
to 9%) for any ICH and 4% (95% CI = 2.3% to 5.6%) for
sICH. (The PRISMA flow chart and table of included
studies are available in Data Supplement S2, available
as supporting information in the online version of this
paper.) The pooled adjusted OR for the association of
antiplatelet use with any ICH was 1.3 (95% CI = 0.7 to
2.5) and with sICH was 1.6 (95% CI = 1.1 to 2.4). The
results of the individual studies in the meta-analysis are
included in Figure 1.
DISCUSSION
In this cohort of 830 tPA-treated stroke patients, we
found no significant association between prethrombo-
lytic antiplatelet use and postthrombolytic risk of either
radiographic or sICH. Unadjusted analyses identified a
trend toward increased risk for both radiographic and
sICH; however, after adjusting for important confound-
ers (age, stroke severity, and hyperglycemia) no signifi-
cant relationship was observed. These confounders
have previously been associated with increased ICH risk
in multivariable analysis.24
Our data also suggest that the risk of radiographic
ICH increases with age, since the point estimates for
the unadjusted absolute risk difference increase across
the age strata, and the fully adjusted model shows pos-
sible excess risk in the group aged 81 years and older.
This is an interesting area of potential future investi-
gation, as the majority of patients included in the
meta-analyses were from the Safe Implementation of
Thrombolysis in Stroke International Stroke Thromboly-
sis Register (SITS-ISTR), which restricted inclusion to
ages 18 to 80 years.12, 15
In addition, the potential protective effect of preexist-
ing tobacco use against symptomatic hemorrhage has
been redemonstrated in this analysis. Nicotine increases
plasminogen activator inhibitor-1 (PAI-1) activity (which
deactivates therapeutic tPA treatment), although in clini-
cal practice better recanalization has been observed in
myocardial infarction and stroke in smokers.25, 26 Since
sICH may represent an end process of brain damage in
situations where recanalization does not occur, one
potential mechanism for the reduction of sICH among
smokers may be better recanalization. It may also reflect
the presence of the higher levels of PAI-1 in smokers,
decreasing the effective half-life of exogenous tPA,
thereby limiting the potential damage as parts of the
ischemic penumbra progress to frank infarction and
Table 2
Characteristics of the Study Population
Characteristics
Antiplatelet Use No Antiplatelet Use
Mean (SD) Mean (SD) Difference (95% Cl)
Age (yr) 74 (12.6) 65 (16) 8.1 6.2 to 10.1*
Onset to treatment (minutes) (n = 780) 148 (40.8) 151 (53.9) –2.7 9.5 to 4.1
Pretreatment
Blood glucose (mg/dL) (n = 820) 137 (55.1) 129 (42.9) 8.5 1.8 to 15.2*
Systolic blood pressure (mm Hg) (n = 826) 151 (21.7) 147 (22) 4.4 1.4 to 7.4*
Diastolic blood pressure (mm Hg) (n = 826) 78 (16.6) 79 (15.3) –0.8 3 to 1.4
NIHSS 13 (5.7) 12 (5.8) 0.8 0.1 to 1.6*
Demographics Percentage (N) Percentage (N) Difference,% 95% Cl
Female 47.7 (185) 46.2 (204) 1.5 5.3 to 8.3
Non-Hispanic white 80.9 (314) 78.3 (346) 2.6 2.9 to 8.2
African American 7.7 (30) 10.0 (44) –2.2 6.1 to 1.7
Other/unknown 11.1 (43) 11.5 (51) –0.5 4.8 to 3.9
Prior stroke 27.6 (107) 9.0 (40) 18.5 13.3 to 23.7*
Prior TIA 18.3 (71) 8.6 (38) 9.7 5.1 to 14.3*
Diabetes mellitus 28.6 (111) 18.8 (83) 9.8 4.1 to 15.6*
Hypertension 86.9 (337) 62.4 (276) 24.4 18.4 to 30.4*
Hyperlipidemia 61.1 (237) 31.2 (138) 29.9 23.1 to 36.6*
Coronary artery disease 50.8 (197) 16.1 (71) 34.7 28.3 to 41.1*
Congestive heart failure 17.0 (66) 7.9 (35) 9.1 4.6 to 13.5*
Atrial fibrillation 31.4 (122) 14.5 (64) 16.9 11.3 to 22.6*
Valvular heart disease 9.8 (38) 4.5 (20) 5.3 1.8 to 8.7*
Smoking within 1 yr 18.8 (73) 30.1 (133) 11.3 17.2 to -5.4
Posttreatment deviations
Antiplatelet given within 24 hours (n = 829) 10.3 (40) 11.5 (51) 1.2 5.5 to 3.1
Anticoagulant given within 24 hours 5.4 (21) 6.6 (29) 1.1 4.4 to 2.1
Blood pressure maintained < 180/105 mm Hg
(n = 816)
21.4 (83) 15.8 (70) 5.6 0.3 to 10.8*
Difference in means or binomial difference in proportions with 95% CI reported calculated by subtracting no antiplatelet use
group from antiplatelet group.
NIHSS = National Institutes of Health Stroke Scale; TIA = transient ischemic attack.
*Items with CIs excluding 0.
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disruption of the blood–brain barrier. Nicotine may
have promise as an agent to enhance the acute effec-
tiveness and safety of tPA, although it may cause postis-
chemic brain inflammation when administered
continuously for days after experimental stroke.27 Fur-
ther studies are warranted, including translational ani-
mal models of thrombolysis-associated hemorrhage.
To put the current investigation in the context of the
previous understanding of the topic, we performed a
structured literature review and used meta-analytic
techniques to quantify how this investigation has
updated our knowledge. Overall, the point estimates for
the radiographic and sICH proportions and aOR from
the current investigation are congruent with the prior
work in this area; however, the overall meta-analysis
did estimate a small but statistically increased adjusted
odds of sICH for patients who were on antiplatelet
agents.
Limitations
This study has several important limitations. First, we
do not have 90-day functional outcomes on the patients
Table 3
Fully Adjusted Models for Any Radiographic ICH and sICH
Characteristics
Model 1: Any ICH Model 2: sICH
aOR (95% CI) Category for Model 2 aOR (95% CI)
Preexisting antiplatelet use 1.13 (0.76–1.68) 1.26 (0.72–2.19)
Post-tPA treatment protocol deviations 1.00 (0.65–1.52) 1.57 (0.90–2.75)
History of tobacco use 0.70 (0.40–1.24) 0.32 (0.11–0.94)
Systolic blood pressure (10 mm Hg increase) 1.07 (0.97–1.17) 1.09 (0.96–1.25)
Onset to treatment time (minutes) 1.00 (0.995–1.004) 0.997 (0.99–1.004)
Baseline NIHSS
1–6 0.29 (0.15–0.55) 1–11 0.53 (0.30–0.95)
7–11 0.33 (0.19–0.55)
12–15 0.72 (0.44–1.17) 12+ Ref.
16+ Ref.
Age (yr)
20–57 0.41 (0.20–0.83) 20–70 0.52 (0.27–1.001)
58–70 0.80 (0.47–1.37)
71–70 0.83 (0.51–1.37) 71+ Ref.
81+ Ref.
Baseline blood glucose (mg/dL)
59–101 0.50 (0.28–0.91) 59–118 1.00 (0.58–1.73)
102–118 0.69 (0.41–1.16)
119–144 0.83 (0.50–1.39) 119+ Ref.
145+ Ref.
Age, severity, and glucose were divided into quartiles (Model 1) or dichotomized (Model 2) to allow for nonlinear effects. Model
1 fit was satisfactory (c-statistic = 0.704; Hosmer and Lemeshow goodness-of-fit test failed to reject hypothesis of lack of fit,
p = 0.76) as was the fit of Model 2 (c-statistic = 0.719; Hosmer and Lemeshow goodness-of-fit test, p = 0.14).
Final models evaluating the relationship between ICH and antiplatelet use.
aOR = adjusted OR; ICH = intracranial hemorrhage; NIHSS = National Institutes of Health Stroke Scale; sICH = symptomatic ICH;
TIA = transient ischemic attack.
Table 4
Any ICH and Symptomatic ICH Stratified by Age
Age, yr
Overall Severity Antiplatelet Use No-Antiplatelet Use Absolute Risk Increase
NIHSS (IQR) No ICH ICH ICH% No ICH ICH ICH% RD,% (95% Cl)
Any ICH
20–57 10 (7–15) 51 5 8.9 128 11 7.9 1.0 (7.5 to 9.5)
58–70 11 (7–15) 79 12 13.2 106 22 17.2 –4.0 (13.7 to 5.7)
71–80 13 (9–17) 96 21 17.9 68 18 20.9 –3.0 (13.9 to 8.0)
81+ 14 (9–18) 87 37 29.8 73 16 18.0 11.9 (0.1 to 23.6)*
Symptomatic ICH
20–57 10 (7–15) 56 0 0.0 135 4 2.9 –2.9 (7.3 to 1.5)
58–70 11 (7–15) 86 5 5.5 120 8 6.3 –0.8 (7.1 to 5.6)
71–80 13 (9–17) 107 10 8.5 79 7 8.1 0.4 (7.3 to 8.1)
81+ 14 (9–18) 104 20 16.1 81 8 9.0 7.1 (2.1 to 16.3)
Binomial difference in proportions with 95% CI reported calculated by subtracting no antiplatelet use group from antiplatelet
group. Stroke severity within each stratum summarized with median NIHSS and IQR.
IQR = interquartile range; NIHSS = National Institutes of Health Stroke Scale; RD = risk difference.
*Items with CIs excluding 0.
ACADEMIC EMERGENCY MEDICINE • February 2013, Vol. 20, No. 2 • www.aemj.org 151
in the study, limiting our ability to determine what con-
tribution the ICH had on the ultimate clinical outcome.
Since many hemorrhages occur in patients with large
strokes (high NIHSS) whose expected outcomes are
poor, it is difficult to separate out the independent effect
of ICH from the influence of a large ischemic stroke.
Another important limitation of our investigation is our
reliance on retrospective medical record review. For
this reason our primary outcome was radiographic evi-
dence of hemorrhage, which is easier to determine
objectively from the medical record. This measure may
be of more limited clinical utility, since small radio-
graphic hemorrhages have not demonstrated impair-
ment of ultimate functional outcome.28 The current
study was powered to identify a relatively large effect
on ICH. Another limitation is the potential confounding
effects of new stroke therapies over the time course of
the study, which spanned 14 years. It is plausible that
greater coexisting use of medications affecting platelet
inhibition, such as statins or selective serotonin reup-
take inhibitors, may complicate this relationship. To the
best of our knowledge, no studies to date have had
adequate numbers of events to detect any synergistic
effects of these agents with antiplatelet use on increas-
ing ICH.29, 30 In addition, increasing numbers of
patients are on alternate antiplatelet agents, particularly
clopidogrel, either alone or in combination. Our current
investigation collected antiplatelet use as a dichotomous
variable, thus precluding inference regarding dosing
and combinations. While subgroup analyses have been
done in some of the prior evaluations, the majority of
included patients have been on aspirin alone. Current
estimates of the potential interaction between clopido-
grel or combination treatments with stroke thromboly-
sis are imprecise; however, it does appear that some
increased risk exists.11 It is important to note that stud-
ies focusing on this have not contained enough patients
on alternative regimens to allow generalizable conclu-
sions for clinical practice. In addition, the antiplatelet
group had a higher burden of vascular risk factors,
which is not surprising; however, when we adjusted for
residual confounding by vascular risk factors using pro-
pensity scores, the associations between antiplatelet use
and hemorrhage were unchanged. Another consider-
ation is the variable use of imaging and increasing use
of MRI. The sensitivity of MRI versus CT for intracranial
blood is an area of controversy in the radiologic litera-
ture, and over this time period it is unlikely that CT or
MRI had substantially different performance.31 Our
finding that ICH did not increase over time, despite the
likely increased popularity of MRI, lends credence to
this, although going forward this may need to be exam-
ined as maximally heme-sensitive sequences on MRI
(gradient echo) are becoming more commonly used. In
addition, we found the rates of radiographic ICH to
actually be lower when follow-up MRI was performed.
Finally, the context analyses were designed to place the
current results in perspective based on other published
data on the topic; as with any form of meta-analysis,
heterogeneity exists across studies, centers, and regions
of the world.
The results of this study, and its combination with
other existing knowledge on this topic, are applicable to
clinical situations that emerge routinely. Since the
Figure 1. Meta-analyses with and without current investigation for risk difference and aORs. Results of meta-analyses.
aOR = adjusted OR; AP = antiplatelet; RD = risk difference; ICH = intracranial hemorrhage; sICH = symptomatic ICH. Risk difference
is the absolute excess proportion of patients with ICH in patient with documented prestroke antiplatelet use versus those without.
For example, in A, 4.9% more antiplatelet patients had radiographic evidence of ICH versus those not receiving antiplatelets when
estimates across all studies were combined.
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adjusted increased odds of symptomatic hemorrhage in
patients receiving antiplatelets is consistently small, it is
likely, at least with respect to aspirin use, that any
increased risk from stroke thrombolysis in patients
receiving aspirin is of questionable importance. Other
clinical variables, most notably stroke severity and age,
appear to be much more important.
CONCLUSIONS
We found no significant increases in either radio-
graphic or symptomatic intracranial hemorrhage fol-
lowing thrombolysis in patients receiving antiplatelet
agents in the Increasing Stroke Treatment through
Interventional Behavior Change Tactics and Safety of
Intravenous Thrombolysis in Four Emergency Depart-
ments studies. The meta-analyses increased the preci-
sion of estimates for the unadjusted proportion and
adjusted odds of intracranial hemorrhage, and showed
that antiplatelet agents may minimally increase symp-
tomatic intracranial hemorrhage. Future work should
focus on the association of antiplatelet use prior to
thrombolysis on functional outcomes, the development
of selection strategies to triage high-risk patients to
treatments, and the discovery of agents that can inhibit
the development of postthrombolysis intracranial hem-
orrhage.
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